Oramed Pharmaceuticals Inc.
ORMPHealthcare|Biotechnology|US
$3.86
-0.03 (-0.77%)
DCF Value
$1.17
Tangible Book / Share
$7.74
Graham Number
$27.23
Cash / Share
$1.23
Financials
Financial Snapshot
Market Cap
$160.6M
Enterprise Value
$146.1M
Revenue (TTM)
$0.00
Net Income (TTM)
$174.9M
Cash & Investments
$50.6M
Net Cash
$49.9M
Free Cash Flow (TTM)
-$5.4M
Operating CF (TTM)
-$5.6M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$50.6M
Quarterly Burn
$1.4M
Monthly Burn
$464.0K
Est. Runway
~36.4 quarters
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $31.0M | $20.1M | $30.5M | $32.3M | $39.9M | $94.1M | $155.7M | $162.0M | $141.9M | $125.9M | $50.6M | |
| Operating Cash Flow | $4.7M | -$5.8M | -$14.7M | -$12.9M | -$12.4M | -$21.2M | -$28.7M | -$10.3M | -$8.4M | -$9.1M | -$5.6M | |
| Free Cash Flow | $4.6M | -$5.8M | -$14.7M | -$13.0M | -$12.5M | -$21.6M | -$29.2M | -$10.5M | -$8.4M | -$11.1M | -$5.4M | |
| Capital Expenditure | -$9.0K | -$7.0K | -$5.0K | -$15.0K | -$82.0K | -$375.0K | -$496.0K | -$254.0K | -$18.0K | -$1.9M | $194.7K | |
| Financing Cash Flow | $12.0M | $1.6M | $22.7M | $0.00 | $23.8M | $101.4M | $11.6M | $52.0M | -$52.0M | -$4.7M | -$16.7M |
R&D Spending
R&D (TTM)
$4.7M
R&D Intensity
—
R&D Growth vs Prior
-25.8%
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $641.0K | $2.5M | $2.4M | $2.7M | $2.7M | $2.7M | $2.7M | $1.3M | $0.00 | $2.0M | $0.00 | |
| R&D Expense | $7.7M | $10.3M | $12.0M | $13.5M | $10.2M | $21.0M | $27.6M | $9.0M | $6.3M | $6.4M | $4.7M | |
| R&D % of Revenue | 1202.7% | 418.6% | 489.1% | 500.3% | 377.7% | 776.5% | 1022.5% | 669.5% | — | 319.1% | — | |
| SG&A | $2.5M | $2.8M | $4.1M | $3.7M | $4.2M | $5.9M | $15.7M | $8.1M | $6.5M | $8.7M | $9.8M |
Income Statement
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $641.0K | $2.5M | $2.4M | $2.7M | $2.7M | $2.7M | $2.7M | $1.3M | $0.00 | $2.0M | $0.00 | |
| Cost of Revenue | $490.0K | $187.0K | $86.0K | $90.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.0M | $61.0K | |
| Gross Profit | $151.0K | $2.3M | $2.4M | $2.6M | $2.7M | $2.7M | $2.7M | $1.3M | $0.00 | $13.0K | -$61.0K | |
| R&D | $7.7M | $10.3M | $12.0M | $13.5M | $10.2M | $21.0M | $27.6M | $9.0M | $6.3M | $6.4M | $4.7M | |
| SG&A | $2.5M | $2.8M | $4.1M | $3.7M | $4.2M | $5.9M | $15.7M | $8.1M | $6.5M | $8.7M | $9.8M | |
| Operating Income | -$10.0M | -$10.8M | -$13.5M | -$14.6M | -$11.8M | -$24.2M | -$40.6M | -$15.8M | -$12.8M | -$15.1M | -$14.5M | |
| Interest Expense | $11.0K | $6.0K | $6.0K | $0.00 | $0.00 | $0.00 | $0.00 | $3.6M | $853.0K | $0.00 | $0.00 | |
| Pretax Income | -$9.6M | -$10.1M | -$12.7M | -$14.1M | -$11.5M | -$23.0M | -$37.7M | $5.1M | -$15.9M | $75.3M | $220.3M | |
| Net Income | -$11.0M | -$10.5M | -$12.7M | -$14.4M | -$11.5M | -$22.2M | -$37.8M | $5.5M | -$19.1M | $64.0M | $174.9M | |
| EPS (Diluted) | -0.87 | -0.79 | -0.86 | -0.82 | -0.56 | -0.78 | -0.97 | 0.14 | -0.48 | 1.50 | 4.11 | |
| EBITDA | -$10.0M | -$10.8M | -$13.5M | -$14.2M | -$11.8M | -$24.1M | -$40.5M | $7.3M | -$14.9M | $75.4M | $151.8M | |
| Shares Out. (M) | 12.62 | 13.31 | 14.88 | 17.45 | 20.53 | 28.47 | 39.00 | 40.57 | 40.85 | 42.42 | 42.50 |
Balance Sheet
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.9M | $4.0M | $5.0M | $3.3M | $19.3M | $77.2M | $40.5M | $9.1M | $54.4M | $45.9M | $15.2M | |
| Short-Term Investments | $27.1M | $16.2M | $25.5M | $29.0M | $20.6M | $16.9M | $115.3M | $153.0M | $87.5M | $79.9M | $35.4M | |
| Total Current Assets | $31.2M | $20.3M | $31.0M | $33.3M | $40.5M | $95.3M | $157.1M | $162.6M | $143.2M | $133.3M | $53.4M | |
| Total Assets | $42.8M | $38.7M | $47.4M | $34.7M | $44.6M | $128.0M | $161.6M | $220.6M | $155.3M | $230.9M | $369.6M | |
| Total Current Liabilities | $3.6M | $5.2M | $4.6M | $5.3M | $4.5M | $6.7M | $5.7M | $53.2M | $5.7M | $19.1M | $10.7M | |
| Long-Term Debt | $14.0K | $18.0K | -$7.8M | -$5.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $16.6M | $19.5M | $16.3M | $15.3M | $11.8M | $11.5M | $10.5M | $57.7M | $9.9M | $31.1M | $52.2M | |
| Stockholders' Equity | $26.2M | $19.2M | $31.1M | $19.4M | $32.9M | $115.8M | $151.8M | $163.8M | $146.3M | $199.7M | $317.5M | |
| Retained Earnings | -$46.0M | -$56.5M | -$69.2M | -$81.1M | -$92.6M | -$114.9M | -$163.1M | -$157.6M | -$176.6M | -$123.4M | -$7.0M |
Cash Flow Statement
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.7M | -$5.8M | -$14.7M | -$12.9M | -$12.4M | -$21.2M | -$28.7M | -$10.3M | -$8.4M | -$9.1M | -$5.6M | |
| Capital Expenditure | -$9.0K | -$7.0K | -$5.0K | -$15.0K | -$82.0K | -$375.0K | -$496.0K | -$254.0K | -$18.0K | -$1.9M | $194.7K | |
| Free Cash Flow | $4.6M | -$5.8M | -$14.7M | -$13.0M | -$12.5M | -$21.6M | -$29.2M | -$10.5M | -$8.4M | -$11.1M | -$5.4M | |
| Investing Cash Flow | -$16.0M | $4.3M | -$7.0M | $11.3M | $4.6M | -$22.3M | $30.2M | -$73.0M | $105.8M | $5.4M | $22.0M | |
| Financing Cash Flow | $12.0M | $1.6M | $22.7M | $0.00 | $23.8M | $101.4M | $11.6M | $52.0M | -$52.0M | -$4.7M | -$16.7M | |
| Issuance of Stock | $12.0M | $1.6M | $22.7M | $0.00 | $23.8M | $101.4M | $11.6M | $2.4M | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.5M | -$4.7M | -$4.4M | |
| Net Debt Issuance | — | — | — | — | — | — | — | $49.5M | -$49.5M | $0.00 | -$10.4M | |
| Stock Based Comp. | $634.0K | $1.6M | $1.5M | $808.0K | $465.0K | $0.00 | $0.00 | $0.00 | $0.00 | $6.0M | $3.7M | |
| Net Change in Cash | $694.0K | $62.0K | $1.0M | -$1.7M | $16.0M | $57.9M | -$36.8M | -$31.4M | $45.4M | -$8.5M | -$552.0K |
Dilution Tracker
Shares outstanding grew 106.6% over 5 years — significant dilution
Shares Outstanding
42M
5-Year Share Growth
+106.6%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 12.62 | 13.31 | 14.88 | 17.45 | 20.53 | 28.47 | 39.00 | 40.57 | 40.85 | 42.42 | 42.50 | |
| Change vs Prior % | — | 5.4% | 11.8% | 17.3% | 17.6% | 38.7% | 37.0% | 4.0% | 0.7% | 3.8% | 0.2% | |
| Stock Issuance | $12.0M | $1.6M | $22.7M | $0.00 | $23.8M | $101.4M | $11.6M | $2.4M | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.5M | -$4.7M | -$4.4M | |
| Stock Based Comp. | $634.0K | $1.6M | $1.5M | $808.0K | $465.0K | $0.00 | $0.00 | $0.00 | $0.00 | $6.0M | $3.7M |
Margins & Profitability
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 23.6% | 92.4% | 96.5% | 96.7% | 100.0% | 100.0% | 100.0% | 100.0% | — | 0.7% | — | |
| Operating Margin % | -1561.6% | -438.6% | -552.3% | -541.3% | -433.8% | -896.2% | -1502.0% | -1176.8% | — | -754.4% | — | |
| Net Margin % | -1710.5% | -426.7% | -519.7% | -531.1% | -424.8% | -822.7% | -1397.1% | 412.3% | — | 3202.5% | — | |
| EBITDA Margin % | -1558.3% | -437.9% | -550.9% | -524.3% | -433.6% | -893.3% | -1499.8% | 546.3% | — | 3772.2% | — | |
| FCF Margin % | 724.8% | -237.7% | -598.7% | -479.3% | -462.1% | -797.5% | -1080.2% | -787.2% | — | -553.9% | — | |
| ROE % | -41.9% | -54.5% | -40.9% | -74.0% | -35.0% | -19.2% | -24.9% | 3.4% | -13.0% | 32.1% | 73.0% | |
| ROA % | -25.6% | -27.1% | -26.9% | -41.4% | -25.8% | -17.4% | -23.4% | 2.5% | -12.3% | 27.7% | 47.3% | |
| ROIC % | -25.5% | -32.1% | -29.6% | -49.8% | -29.3% | -19.9% | -26.0% | -7.2% | -8.5% | -6.0% | -3.2% | |
| R&D / Revenue % | 1202.7% | 418.6% | 489.1% | 500.3% | 377.7% | 776.5% | 1022.5% | 669.5% | — | 319.1% | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 283.2% | -0.3% | 10.4% | 0.3% | -0.3% | 0.0% | -50.4% | -100.0% | 0.0% | |
| Gross Profit | 0.0% | 1402.6% | 4.1% | 10.6% | 3.7% | -0.3% | 0.0% | -50.4% | -100.0% | 0.0% | |
| Operating Income | -35.6% | -7.6% | -25.6% | -8.2% | 19.6% | -106.0% | 0.0% | 61.2% | 18.9% | -18.1% | |
| Net Income | -51.6% | 4.4% | -21.4% | -12.8% | 19.8% | -93.2% | 0.0% | 114.6% | -445.0% | 436.0% | |
| EPS (Diluted) | -29.9% | 9.2% | -8.9% | 4.7% | 31.7% | -39.3% | 0.0% | 114.4% | -442.9% | 412.5% | |
| Operating Cash Flow | 194.1% | -225.3% | -151.4% | 11.7% | 3.9% | -70.3% | 0.0% | 64.1% | 18.3% | -8.7% | |
| Free Cash Flow | 193.9% | -225.7% | -151.1% | 11.6% | 3.3% | -72.1% | 0.0% | 63.9% | 20.1% | -31.4% | |
| R&D Expense | 61.2% | 33.4% | 16.5% | 12.9% | -24.3% | 105.1% | 0.0% | -67.5% | -29.5% | 0.9% | |
| SG&A Expense | -5.8% | 12.5% | 48.0% | -8.8% | 13.7% | 40.3% | 0.0% | -48.0% | -20.7% | 35.0% | |
| Total Assets | 62.5% | -9.6% | 22.4% | -26.9% | 28.8% | 186.8% | 0.0% | 36.4% | -29.6% | 48.7% | |
| Book Value / Share | -9.6% | -30.3% | 44.6% | -46.9% | 44.1% | 155.6% | 0.0% | 4.2% | -11.9% | 35.6% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 610.7% | 0.0% | 5674.3% | -99.3% | 121.8% | |
| Diluted Shares | 16.7% | 5.4% | 11.8% | 17.3% | 17.6% | 38.7% | 0.0% | 4.0% | 0.7% | 3.8% |
Valuation
P/E (TTM)0.91
P/S0.00
10Y Low / Med / High21.44 / 59.00 / 207.28
P/B0.50
10Y Low / Med / High0.57 / 2.99 / 5.98
EV/EBITDA0.96
EV/Revenue0.00
10Y Low / Med / High19.35 / 45.26 / 178.90
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.17
Tangible Book / Share
$7.74
Net Current Assets / Share
$0.03
Graham Number
$27.23
Cash / Share
$1.23
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -8.29 | -10.95 | -5.76 | -4.05 | -6.23 | -25.23 | -12.40 | 16.50 | -5.04 | 1.86 | 0.91 | |
| P/S Ratio | 142.00 | 46.88 | 30.08 | 21.44 | 26.44 | 207.28 | 173.56 | 69.50 | 0.00 | 59.00 | 0.00 | |
| P/B Ratio | 3.48 | 5.98 | 2.37 | 2.99 | 2.18 | 4.84 | 3.09 | 0.57 | 0.68 | 0.59 | 0.50 | |
| EV/EBITDA | -8.72 | -10.33 | -5.09 | -3.85 | -4.46 | -20.03 | -10.60 | 18.54 | -3.01 | 0.97 | 0.96 | |
| EV/Revenue | 135.90 | 45.26 | 28.04 | 20.21 | 19.35 | 178.90 | 158.92 | 101.26 | 0.00 | 36.44 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
3.31
Safe
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 |
|---|---|---|
| Revenue | $1.2M | $778.6K |
| Net Income | $189.6M | -$34.8M |
| EPS | $4.47 | $-0.82 |
| # Analysts (EPS) | 1 | 1 |
Dividends
Dividend/Share (TTM)
$0.25
Dividend Yield
6.48%
Frequency
Special
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Jan 16, 2026 | Jan 26, 2026 | $0.25 | Special |